Nearly a year ago, Merck struck a $10.8 billion deal to acquire Prometheus Biosciences, a clinical-stage company whose technology platform analyzed genetics and biology data to discover new drugs. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback